Entering text into the input field will update the search result below

Kiadis inks license deal with Sanofi valued as high as €875M

Jul. 08, 2020 7:13 AM ETKiadis Pharma N.V. (KIADF) Stock, SNY StockSNY, KIADFBy: Douglas W. House, SA News Editor
  • Kiadis Pharma N.V. (OTC:KIADF) has granted an exclusive global license to its K-NK004 cell program to Sanofi (NASDAQ:SNY), including exclusive rights to its K-NK platform for two other preclinical programs (excluding K-NK002 and K-NK003).
  • Under the terms of the deal, Kiadis will receive €17.5M upfront, up to €857.5M in milestones and low-double digit royalties on net sales.
  • The agreement covers Kiadis' proprietary CD38 knockout K-NK therapeutic for use in combination with Sanofi's Sarclisa (isatuximab-irfc), a CD38-directed cytolytic antibody approved in the U.S. four months ago and in Europe last month for treatment-resistant multiple myeloma (MM).
  • Kiadis says the combination of its CD38 knockout K-NK cells with Sarclisa has the potential to be the first-in-class treatment for MM.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
SNY
--
KIADF
--